Waters Corporation (NYSE: WAT) today announced that the Chinese Food and
Drug Administration (CFDA) approved the Waters® ACQUITY UPLC®
I- Class IVD/Xevo® TQ-S IVD System for in vitro
diagnostic (IVD) use in China. The system was approved for clinical
analysis of a variety of compounds that include diagnostic indicators
and compounds for treatment monitoring.
"The practice of medicine is changing from a reactive approach to
treating disease, to one that is more proactive and preventive," said
Jeff Mazzeo, Senior Director, Health Sciences for Waters Division. "To
facilitate this transition, better diagnostic and predictive tools are
needed so that disease can be detected earlier or even prevented. That
is where Waters technologies like the ACQUITY® TQD System and
ACQUITY UPLC I-Class IVD/Xevo TQ-S IVD systems, approved for IVD use by
the CFDA in 2014 and 2015, respectively, can make a significant impact."
Using LC-MS technology, clinical laboratories perform qualitative and
quantitative analyses of patients' samples to aid clinicians in many
ways. These tests may be used to confirm a clinical suspicion (including
making a diagnosis); assist in the selection, optimization and
monitoring of treatment; provide a prognosis; screen for disease in the
absence of clinical signs or symptoms; and establish and monitor the
severity of physiological disturbance. Liquid chromatography separates
analytes and interferents within a given sample, while mass spectrometry
technology is used for detection and confirmation of those analytes.
The recently CFDA approved ACQUITY UPLC I-Class IVD/Xevo TQ-S IVD System
features Waters' UltraPerformance LC® technology coupled with
a tandem quadrupole mass spectrometer designed for the most demanding
UPLC-MS/MS quantitative analysis. This system uses StepWave™, a
breakthrough off-axis ion source technology, and RADAR™, an information
rich acquisition method, enabling the system with sensitivity and
robustness.
For more information, please visit Waters'
Clinical application page.
About Waters Corporation (www.waters.com)
For over 50 years, Waters Corporation (NYSE: WAT) has been enabling
significant progress in the fields of healthcare, environmental
management, food safety, and global water quality monitoring by
providing practical and sustainable innovations, thus creating business
advantages for laboratory-associated organizations.
As a pioneer in separation science, laboratory information management,
mass spectrometry, and thermal analysis technology, Waters has created a
sustainable platform with its technical breakthroughs and laboratory
solutions for the success of its clients.
Waters achieved revenues of $ 1.99 billion in 2014, and it will continue
to lead its clients to explore science and achieve excellence.
Waters, ACQUITY, ACQUITY UPLC, UPLC, XEVO, StepWave and RADAR are
trademarks of Waters Corporation.
Copyright Business Wire 2015